STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 998-1008

  Nguyen, Andrew V ^a   Wu, Yuan Yuan ^b   Liu, Qiang ^b   Wang, Donghai ^b   Nguyen, Stephanie ^c   Loh, Ricky ^a   Pang, Joey ^a   Friedman, Kenneth ^b   Orlofsky, Amos ^b   Augenlicht, Leonard ^b   Pollard, Jeffrey W ^b   Lin, Elaine Y ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WILLIAMS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL28 CHEMOKINE; CHEMOKINE; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PHOSPHOTRANSFERASE; RANTES; SPHINGOSINE 1 PHOSPHATE KINASE 1; SPHINGOSINE 1 PHOSPHATE KINASE 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DYSPLASIA; EPITHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CCL19; CHEMOKINE CCL5; CHEMOKINES, CC; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; RECEPTORS, LYSOSPHINGOLIPID; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84884376190     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13952     Document Type: Article

References (52)

1. Joyce JA and Pollard JW (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252.
2. Mantovani A, Allavena P, Sica A, and Balkwill F (2008). Cancer-related inflammation. Nature 454, 436-444.
3. Karin M and Greten FR (2005). NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5, 749-759.
4. Yu H, Kortylewski M, and Pardoll D (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51.
5. Yu H, Pardoll D, and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798-809.
6. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11, 1314-1321.
7. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10,48-54.
8. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, and Akira S (1999). Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49.
9. -/- mice: an overview. J Leukoc Biol 61, 389-396.
10. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, Orlofsky A, Liu Q, Hume DA, Pollard JW, et al. (2010). A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 176, 952-967.
11. Ernst M and Putoczki TL (2012). Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 39, 711-718.
12. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, and Weinstein IB (2002). Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62, 3351-3355.
13. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, and Behrmann I (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 18, 3742-3753.
14. Stephanou A, Brar BK, Knight RA, and Latchman DS (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7, 329-330.
15. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
16. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al. (2005). Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7, 545-555.
17. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/ STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167, 969-980.
18. Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, Brown ML, and Dritschilo A (2013). STAT3 suppresses transcription of pro apoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci USA 110, 1267-1272.
19. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, and Murai M (2002). Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168, 762-765.
20. Kawada M, Seno H, Uenoyama Y, Sawabu T, Kanda N, Fukui H, Shimahara Y, and Chiba T (2006). Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of β-catenin in colorectal cancer. Cancer Res 66, 2913-2917.
21. Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, et al. (2011). STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17, 1452-1462.
22. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40, 955-962.
23. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al. (2009). gp130mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102.
24. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, Hannun YA, and Obeid LM (2009). Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 23, 405-414.
25. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, and Obeid LM (2009). A role for sphingosine kinase 1 in dextran sulfate sodiuminduced colitis. FASEB J 23, 143-152.
26. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et al. (2013). Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23, 107-120.
27. el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, Louvard D, Chambon P, Metzger D, and Robine S (2004). Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186-193.
28. Rigas B, Tsioulias GJ, Allan C, Wali RK, and Brasitus TA (1994). The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 83, 319-323.
29. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, et al. (2006). Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12, 20-28.
30. Hori S, Nomura T, and Sakaguchi S (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061.
31. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al. (2010). STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 16, 1421-1428.
32. Olivera A, Kohama T, Tu Z, Milstien S, and Spiegel S (1998). Purification and characterization of rat kidney sphingosine kinase. JBiolChem273, 12576-12583.
33. Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, et al. (2010). VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 207, 2855-2868.
34. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113.
35. Muller S, Lory J, Corazza N, Griffiths GM, Z'Graggen K, Mazzucchelli L, Kappeler A, and Mueller C (1998). Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol 152, 261-268.
36. Okazaki K, Morita M, Nishimori I, Sano S, Toyonaga M, Nakazawa Y, and Yamamoto Y (1993). Major histocompatibility antigen-restricted cytotoxicity in inflammatory bowel disease. Gastroenterology 104, 384-391.
37. Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, Lee CW, Horwitz BH, Fox JG, Ge Z, et al. (2010). Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer 126, 1651-1665.
38. Atreya I and Neurath MF (2008). Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8, 561-572.
39. Deschoolmeester V, Baay M, Lardon F, Pauwels P, and Peeters M (2011). Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron 4, 377-392.
40. Ladoire S, Martin F, and Ghiringhelli F (2011). Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60, 909-918.
41. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, and Iacopetta B (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27, 186-192.
42. Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, and Adams DH (2006). Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol 177, 593-603.
43. + regulatory T cells. J Exp Med 194, 847-853.
44. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, and Linehan DC (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. JImmunol182, 1746-1755.
45. Grivennikov S and Karin M (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13, 7-9.
46. Gurgui M, Broere R, Kalff JC, and van Echten-Deckert G (2010). Dual action of sphingosine 1-phosphate in eliciting proinflammatory responses in primary cultured rat intestinal smooth muscle cells. Cell Signal 22, 1727-1733.
47. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367, 1596-1606.
48. Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, and Pchejetski D (2013). Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res 117, 143-200.
49. Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, and Sumbayev VV (2011). The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol 89, 268-274.
50. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, and Cyster JG (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360.
51. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, et al. (2002). Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62, 1410-1419.
52. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, and Stein JM (2007). FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. JImmunol178, 2458-2468.